Examples of using Amgen in English and their translations into Thai
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
If you agree to these Terms, then Amgen grants to you a personal, nonexclusive, nontransferable and limited license(without the right to sublicense) to access and use the Services and download, print and/or copy Amgen Content solely for your own use and subject to these Terms.
Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives.
Amgen will take appropriate technical and organizational measures, both at the time of the design of the processing system and at the time of the processing itself, in order to maintain security and prevent unauthorized processing.
By agreeing to receive text messages, you understand and agree that Amgen may use an automatic dialing system to deliver text messages to you and that your consent to receive text messages is not required as a condition of purchase for any goods or services.
Where required by applicable laws, rules and regulations we will disclose personal information to regulatory authorities and ethics committees and/or in certain limited circumstances, Amgen may be required to release your personal information in response to a court order, subpoena, search warrant, law, or regulation.
At Amgen, we believe drug discovery starts with a deep understanding of biology. This understanding guides the critical choice of which disease target to pursue, and it also allows us to choose the right tool for that target-the modality, or structural template, most likely to optimize efficacy and safety.
Amgen, one of the world's leading biotechnology companies, opened its Thailand office in 2015, in order to make its innovative medicines available to Thailand patients suffering from serious illnesses. Amgen also looks forward to being an active member of the local biotechnology community and helping to advance the growth of this industry in Thailand.
You acknowledge and agree that the above limitations of liability, together with the other provisions in these Terms that limit liability, are essential terms and that Amgen would not be willing to grant you the rights set forth in these Terms but for your agreement to the above limitations of liability.
Please note: By agreeing to these Terms, you explicitly agree that any claims or actions that you may otherwise have against Amgen under the laws of any jurisdiction outside Thailand are hereby waived and that your sole location and applicable law for any dispute is in Thailand according to the terms of Section 13.
If Amgen is or you are prevented from performing or unable to perform any obligation under these Terms due to any cause beyond the reasonable control of the party invoking this provision, the affected party's performance will be extended for the period of delay or inability to perform due to such cause.
Amgen agrees to indemnify you for any direct damages that you suffer arising out of or related to any suit, action of proceeding by a third party to the extent such direct damages arise from a claim that your use of the Services in compliance with these Terms infringes a third party's U.S.
Our teams work quickly to move scientific breakthroughs from the lab through the clinic to the marketplace and to support other aspects of our business. Diverse teams working together generate the best decisions for patients, staff and stockholders. Our team structure provides opportunities for Amgen staff to impact the direction of the organization, to gain broader perspective about other functions within Amgen and to reach their full potential.
Moreover, Amgen has integrated this broad modality platform into a single drug discovery organization. We have broken down the silos that typically separate small, medium, and large molecule scientists to enhance teamwork and create cross-fertilization among diverse skill sets. Our goal is to ensure a"Biology First" approach to discovery by eliminating stand-alone groups that look at disease through the lens of a single drug modality.
In recent years, ultra-high-throughput DNA sequencing has accelerated the search for genetic variants that are strongly linked to disease risk. Through our acquisition of deCODE Genetics, Amgen is advancing an early-stage pipeline based on newly discovered genes with exciting potential. This strategy builds upon Amgen's record of turning genetic insights into new medicines. Seven Amgen therapies approved for use in patients can be traced back to genes first cloned in our own labs.
If you are a healthcare professional or a healthcare organization, it is your responsibility to obtain your patient's authorization and consent to provide his or her health-related personal information to Amgen through our Websites. By submitting any such information, you represent and warrant that you have obtained your patient's authorization to do so. Please note that patient information may not be disclosed on an Amgen discussion forum or chat room.
To successfully pursue new targets emerging from genetics, we benefit greatly from Amgen core strengths in biology and protein engineering. Newly discovered disease genes may code for proteins with unknown functions, and these novel proteins may also prove very hard to engage with standard types of drugs. To interdict challenging targets, we need to elucidate complex biology before choosing the best drug modality from our toolkit-or engineering a new modality.
Amgen's Websites feature links to other Websites that we believe you might find useful and informative. Please be aware, however, that we do not endorse or recommend these Websites' content or services, and we are not responsible for the privacy practices of these other Websites. We encourage you to be aware of and read the privacy policy of each Website you visit. Remember, the statements in this Privacy Statement apply solely to information collected by Amgen.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
The Services may contain information, news and/or press releases about Amgen. While this information was believed to be accurate as of the date it was prepared, Amgen disclaims any duty or obligation to update this information, news or any press releases. Information about companies other than Amgen contained in the news, press releases or otherwise, should not be relied upon as being provided or endorsed by Amgen. .
Amgen aspires to be the best human therapeutics company.